Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2019

Nov 13, 2019

SELL
$20.03 - $40.08 $500,750 - $1 Million
-25,000 Closed
0 $0
Q2 2019

Aug 14, 2019

SELL
$25.78 - $39.77 $644,500 - $994,250
-25,000 Reduced 50.0%
25,000 $900,000
Q1 2019

May 14, 2019

SELL
$22.09 - $39.21 $1.1 Million - $1.96 Million
-50,000 Reduced 50.0%
50,000 $1.58 Million
Q4 2018

Feb 13, 2019

SELL
$19.89 - $30.02 $994,500 - $1.5 Million
-50,000 Reduced 33.33%
100,000 $2.51 Million
Q3 2018

Nov 14, 2018

SELL
$12.1 - $28.85 $2.24 Million - $5.34 Million
-185,000 Reduced 55.22%
150,000 $4.33 Million
Q2 2018

Aug 14, 2018

SELL
$7.93 - $15.79 $1.82 Million - $3.63 Million
-229,600 Reduced 40.67%
335,000 $4.1 Million
Q1 2018

May 15, 2018

SELL
$5.18 - $7.97 $1.99 Million - $3.06 Million
-383,400 Reduced 40.44%
564,600 $4.5 Million
Q4 2017

Feb 13, 2018

SELL
$3.98 - $7.37 $1.3 Million - $2.4 Million
-325,800 Reduced 25.58%
948,000 $6.96 Million
Q3 2017

Nov 13, 2017

BUY
$1.33 - $4.12 $1.69 Million - $5.25 Million
1,273,800
1,273,800 $4.71 Million

Others Institutions Holding CDNA

About CareDx, Inc.


  • Ticker CDNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 53,458,100
  • Market Cap $1.15B
  • Description
  • CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for...
More about CDNA
Track This Portfolio

Track Paragon Associates & Paragon Associates Ii Joint Venture Portfolio

Follow Paragon Associates & Paragon Associates Ii Joint Venture and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Paragon Associates & Paragon Associates Ii Joint Venture, based on Form 13F filings with the SEC.

News

Stay updated on Paragon Associates & Paragon Associates Ii Joint Venture with notifications on news.